Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease | Zendy

Shohei Hamada | Zendy; Eikichi Ihara | Zendy; Hiroko Ikeda | Zendy; Kazumasa Muta | Zendy; Haruei Ogino | Zendy; Takatoshi Chinen | Zendy; Yoshimasa Tanaka | Zendy; Yoshihiro Ogawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease

Author(s) -

Shohei Hamada,

Eikichi Ihara,

Hiroko Ikeda,

Kazumasa Muta,

Haruei Ogino,

Takatoshi Chinen,

Yoshimasa Tanaka,

Yoshihiro Ogawa

Publication year - 2019

Publication title -

digestion

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000503340

Subject(s) - medicine , gastroenterology , gerd , reflux , refractory (planetary science) , heartburn , gastric acid , proton pump inhibitor , disease , stomach , physics , astrobiology

The newly developed vonoprazan (a potassium-competitive acid blocker) has a greater ability to suppress gastric acid production than convention proton pump inhibitors (PPIs). The objective of the present study was to determine how vonoprazan influences the pathogenesis of refractory gastroesophageal reflux disease (GERD) in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research